2cureX ( ) - 株価, ニュースと分析OM:2CUREX

2CUREX 株式概要

2cureX AB (publish)はヨーロッパで医療技術会社として活動している。

2CUREX ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

リスク分析

キャッシュランウェイが1年未満である

収益が 100 万ドル未満 ( SEK2M )

意味のある時価総額がありません ( SEK8M )

過去5年間で収益は年間34.3%減少しました。

+1 さらなるリスク

2cureX AB (publ) 競合他社

Evolear

NGM:EVOL

SEK 5.5m

Qlife Holding

OM:QLIFE

SEK 5.8m

Alteco Medical

NGM:ALTE

SEK 17.3m

Vibrosense Dynamics

NGM:VSD B

SEK 12.0m

価格と性能

の歴代最高値、変動、値下がりまとめ2cureX
過去の株価
現在の株価	SEK 0.45
52週高値	SEK 2.95
52週安値	SEK 0.20
ベータ	0.54
11ヶ月の変化	-30.31%
3ヶ月変化	-3.46%
1年変化	-84.88%
33年間の変化	-97.03%
5年間の変化	-96.85%
IPOからの変化	-94.46%

Recent updates

株主還元

	2CUREX	SE Medical Equipment	SE 市場
7D	-20.4%	-4.8%	-1.4%
1Y	-84.9%	5.6%	20.7%

業界別リターン: 2CUREX過去 1 年間で5.6 % の収益を上げたSwedish Medical Equipment業界を下回りました。

リターン対市場: 2CUREXは、過去 1 年間で20.7 % のリターンを上げたSwedish市場を下回りました。

価格変動

Is 2CUREX's price volatile compared to industry and market?
2CUREX volatility
2CUREX Average Weekly Movement	18.7%
Medical Equipment Industry Average Movement	7.2%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	10.9%
10% least volatile stocks in SE Market	3.2%

安定した株価: 2CUREXの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: 2CUREXの週次ボラティリティは過去 1 年間で30%から19%に減少しましたが、依然としてSwedish株の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2006	14	Ole Thastrup	www.2curex.com

2cureX AB (publ)社は、欧州で医療技術企業として活動している。同社の主要製品は体外診断用医薬品検査であるIndiTreatで、がん患者の様々な薬剤に対する反応性や耐性を予測し、適切な治療法を選択するのに役立つ。また、大腸がん、卵巣がん、膵臓がんを対象としたIndiTreatの様々な臨床プログラムを実施している。同社は2006年に法人化され、デンマークのコペンハーゲンを拠点としている。

2cureX AB (publ) 基礎のまとめ

2cureX の収益と売上を時価総額と比較するとどうか。
2CUREX 基礎統計学
時価総額	SEK 7.85m
収益（TTM）	-SEK 26.35m
売上高(TTM)	SEK 1.98m

4.0x

P/Sレシオ

-0.3x

PER（株価収益率

2CUREX は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
2CUREX 損益計算書（TTM）
収益	SEK 1.98m
売上原価	SEK 9.61m
売上総利益	-SEK 7.63m
その他の費用	SEK 18.72m
収益	-SEK 26.35m

直近の収益報告

Jun 30, 2024

次回決算日

Nov 21, 2024

一株当たり利益（EPS）	-1.50
グロス・マージン	-386.18%
純利益率	-1,333.30%
有利子負債／自己資本比率	0%

2CUREX の長期的なパフォーマンスは？

過去の実績と比較を見る

2CUREX 株式概要

報酬

リスク分析

2cureX AB (publ) 競合他社

NGM:EVOL

SEK 5.5m

OM:QLIFE

SEK 5.8m

NGM:ALTE

SEK 17.3m

NGM:VSD B

SEK 12.0m

価格と性能

最新ニュース

2cureX AB (publ) Approves the Election of New Board Members

First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023)

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

Recent updates

2cureX AB (publ) Approves the Election of New Board Members

First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023)

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?